This once-hypothetical scenario is fast becoming a reality. European cannabis reform has become a question of how, not if.

Hanway teams up with Savills and CambridgeHOK to help British farmers, food companies and landowners capitalise on medical cannabis opportunities.

With its wide array of uses, who should be regulating a substance with as many facets at CBD?

Hanway Associates hire new CFO, Sam Lewis, from PwC.

In a historic event that will be closely watched across the world, Canada today becomes the first G7 country to legalise cannabis for recreational use.

The UK government has laid historic new regulations rescheduling cannabis-based medicine, which will come into force on 1st November 2018.

Hanway Associates CEO George McBride spoke at the Conservative Party Conference and Cannabis Invest UK this week on developments in the UK and European Cannabis industry.

On September 21st the UK government announced how they would define cannabis-based products for medicinal use. Following the conclusion of the two part review by the Chief Medical Officer and the ACMD on July 25th, Home Secretary Sajid Javid committed to swift action on the matter, and promised that these products would be lawful by autumn.

This is the first in a blog series profiling exciting companies, projects and people who are paving the way in the UK cannabis space. Separating The Strains is a documentary, currently in production, that explores medical cannabis treatments for epilepsy patients and others. 

Despite cannabis being the most used illicit drug in the UK, little is known about the true scale of the UK cannabis market.

Hanway Associates partner George discussing the risks & opportunities for investors in the growing North American cannabis industry.

Hanway Associates partner Dr Henry Fisher writing about 'Spice' in The Guardian